GENOSEPT
GENOSEPT: Genetics of Sepsis in Europe
It is hypothesized that the fatal outcome following treatment for severe sepsis is, in part, genetically determined. This hypothesis is based on preliminary data developed by several groups from studies of small, relatively homogeneous populations. GenOSept will test this hypothesis through three phases:
-
Harmonization of standards for European high throughput genotyping and quality control by co-ordinating three major European genotyping centres (Wellcome Trust Centre for Human Genetics - Oxford, Cochin Institute - Paris, Helmholtz Zentrum Munchen - Munich).
The project is no longer financed by the European COmmission, but continues to recruit patients and perform Genotyping. Contact Makbule Kobilay for more information.
More Information
More information on the project, its consortium, national coordinators, as well as annual reports can be found on www.genosept.eu
Please find here the Guidelines for the conduct of Collaborative Research using the GenOSept resource
This project is supported by the ECCRN of the ESICM.
GenOSept benefited from a grant of the European Union 6th Framework-programme of RTD.
 |